- Home
- MTRX vs ZBIO Comparison
MTRX vs ZBIO Comparison
Compare MTRX & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- ZBIO
- Stock Information
- Founded
- MTRX 1984
- ZBIO 2019
- Country
- MTRX United States
- ZBIO United States
- Employees
- MTRX N/A
- ZBIO N/A
- Industry
- MTRX Engineering & Construction
- ZBIO
- Sector
- MTRX Consumer Discretionary
- ZBIO
- Exchange
- MTRX Nasdaq
- ZBIO NYSE
- Market Cap
- MTRX 327.8M
- ZBIO 389.2M
- IPO Year
- MTRX 1990
- ZBIO 2024
- Fundamental
- Price
- MTRX $12.97
- ZBIO $9.09
- Analyst Decision
- MTRX Strong Buy
- ZBIO Strong Buy
- Analyst Count
- MTRX 1
- ZBIO 7
- Target Price
- MTRX $20.00
- ZBIO $32.29
- AVG Volume (30 Days)
- MTRX 218.5K
- ZBIO 147.9K
- Earning Date
- MTRX 05-07-2025
- ZBIO 05-27-2025
- Dividend Yield
- MTRX N/A
- ZBIO N/A
- EPS Growth
- MTRX N/A
- ZBIO N/A
- EPS
- MTRX N/A
- ZBIO N/A
- Revenue
- MTRX $742,408,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- MTRX $19.64
- ZBIO N/A
- Revenue Next Year
- MTRX $23.51
- ZBIO N/A
- P/E Ratio
- MTRX N/A
- ZBIO N/A
- Revenue Growth
- MTRX N/A
- ZBIO N/A
- 52 Week Low
- MTRX $8.61
- ZBIO $5.83
- 52 Week High
- MTRX $15.75
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- MTRX 58.52
- ZBIO N/A
- Support Level
- MTRX $10.01
- ZBIO N/A
- Resistance Level
- MTRX $13.80
- ZBIO N/A
- Average True Range (ATR)
- MTRX 0.94
- ZBIO 0.00
- MACD
- MTRX 0.19
- ZBIO 0.00
- Stochastic Oscillator
- MTRX 78.16
- ZBIO 0.00
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.